News

JEM editors selected the last publication from Belot A. and Mathieu A.L. (LYACTS Team) for a highlight article :

Identification of monogenic causes of immune dysregulation provides insight into human immune response and signaling pathways associated with autoimmunity. Here, Jeanpierre et al. (https://doi-org.proxy.insermbiblio.inist.fr/10.1084/jem.20232337) identify new germline variants in the gene encoding PTPN2 associated with loss of regulatory function, enhanced JAK/STAT signaling, and early-onset autoimmunity.

Several studies recently highlighted the role of lipoprotein receptors in viral entry. These receptors are evolutionarily ancient proteins, key for transport of lipids as well as other signaling molecules across the plasma membrane. Here, we discuss the different families of lipoprotein receptors and how they are hijacked by enveloped viruses to promote their entry into infected cells. While the usage of lipoprotein receptors was known for members of Flaviviridae family and for vesicular stomatitis virus, the last four years have seen the discovery that these receptors are used by many genetically unrelated viruses. We also emphasize how viral particles interact with these receptors and the possible targeting of these host factors as antiviral strategies.

Want to read more: https://doi.org/10.1016/j.jbc.2024.107849

On Friday, June 14, collaborative (or competitive!) games livened up the outdoor space of the Rosalind Franklin building. CIRI members came to play, chat and share a nice moment together.

Later on, a giant paella was shared during a festive meal!

Thank you to the organizers, and to all the participants!

Pictures from the party:

      ​

Endogenous retroviruses, very ancient viruses that integrated into human genome, make a stop this month in Spain. They have been intensively studded by researchers from 5 different European countries, within a HERVCOV project, funded by EU Commission. This project is focused on the viral HERV-W-ENV protein, a molecule found to be induced during SARS-CoV-2 infection and present at high levels in the blood of patients with severe COVID-19 and has been associated to “long COVID” disorders. 

The Consortium Meeting 2024

Two days of meetings, intense debates and networking were held on 20 and 21 May in Zaragoza. Most of the researchers involved in the HERVCOV project gathered at the Centro de Investigación Biomédica Aragón (CIBA) of the Instituto Aragonés de Ciencias de la Salud, where the various representatives of the work packages presented the progress of the last year.

The 2nd day of the meeting was characterized by an outreach event for general public where families, youngsters, students and citizens can have: a “virtual” walk in the HERVCOV laboratories by using virtual reality, play a challenging quiz with prizes discovering endogenous retroviruses or playing “Biology challenge”, an outreach game based on DOBBLE created by Bioscienza Responsabile, the Italian association for science communication composed by University of Rome “Tor Vergata” researchers and partner of Frascati Scienza network.

The objectives of the project

The overall objective of HERVCOV project is to analyze the role of these HERVs in the immunopathogenesis of COVID-19 and to identify and evaluate the set of biomarkers which will be important for the diagnosis, prognosis and follow-up of COVID-19 patients and their prioritization for targeted therapy.

One of the objectives of the project is focused on the analysis of the cellular and molecular mechanism of SARS-CoV-2 induced activation of uman endogenous retrovirus (HERVs). The first year of the research has demonstrated that that in vitro exposure to SARS-CoV-2 activates the expression of the HERV-W proinflammatory envelope protein.

The study within the HERVCOV project aims to determine the transcriptomic biomarkers to discriminate bioclinical profiles associated to COVID-19 for individualized medicine. It is supposed to generate high-quality high-throughput sequencing datasets in well-defined biological samples and patients, to be able to define the HERV transcriptional profile of COVID-19 and the long COVID patients. Last but not least, the researchers would like to define the HERVs associated biomarker panel for patient stratification, diagnostic guidelines and prognosis of COVID-19. Clinical and biochemical markers have been analyzed to define a panel of markers that discriminates between Long Covid patients and healthy controls.

The Partners

HERVCOV is the name of the project funded by the European Commission with a grant of almost 7 million euros that involves research centers, companies and associations from Croatia, France, Greece, Italy and Spain. HERVCOV, “SARS-CoV-2-induced activation of pathogenic endogenous retrovirus envelope HERV-W: towards personalized treatment of COVID-19 patients” is funded under the HORIZON-HLTH-2021-DISEASE call (Personalised medicine and infectious disease: understanding the individual host response to viruses) of the European Commission under the Horizon Europe Framework Programme and it involves the following partners: Institut National de la Santé et de la Recherche Médicale (France), Ethniko Kai Kapodistriako Panepistimio Athinon (Greece), Rome Tor Vergata University (Italy), Instituto Aragonés de Ciencias de la Salud (Spain), Fundación Agencia Aragonesa para la Investigación y el Desarrollo (Spain), Geneuro Innovation SAS (France), Inserm Transfert (France), Klinicki Bolnicki Centar Rijeka (Croatia) and Frascati Scienza (Italy). This project has received funding from the European Union’s Horizon Europe research and innovation program under grant agreement No 101057302.

In bars in Lyon and Saint-Etienne, as in 52 other cities in France, the Pint of Science festival brought science to a curious and enthusiastic public. CIRI members helped make this event, which links research and society, a success.

Lyon: What are viruses and how can we study them without dying?

On May 15, 40 people came to the Tire-toi une bûche bar to find out how pathogenic viruses are studied in the laboratory. 

6 years after discovering the festival as a spectator, Maureen Ritter (PhD student in virology, EVIR team) joined the presenter's side. She explained virology techniques in an easy-to-understand way. It's also an opportunity to talk about living things in a broader sense. For example, “Is a virus alive?” presents the criteria for living organisms and highlights the blurring of the boundary, even for experts in the field. 

The evening takes place in a good atmosphere, demystifying science and answering questions about viruses. It's a moment of sharing that gets people's heads out of the lab: “It's great to see that what we do in research is interesting for people who don't do it for a living!

Saint-Etienne: the hidden side of the festival

The GIMAP team proudly represents CIRI in the Saint-Etienne organization of the festival! Aurélien Peyron (PhD student) is coordinator for the city of Saint-Etienne, and other team members are also involved: Jade Majorel (PhD student), Lily Bruyère (work-study student), Alicia Eymaron (student).

From finding speakers to scouting bars, the organizing team oversees the hidden side of the festival. Brought together by a passion for science and popularizing it to the general public, they also share moments of conviviality even before the festival. During the festival, they accompany the speakers and host the evening events. And there's no shortage of entertainment! A general science quiz is designed to arouse the curiosity of participants, who then take part in a Cluedo about rocks for example (presentation by Maeva Darnault, PhD student - Laboratoire LGL-TPE, Université de Lyon and Université Jean Monnet). 

It's an opportunity to open up science to a wider public. Aurélien recounts the experience of a group of young people who stumbled upon the presentations by chance, and were hooked. It's also an interdisciplinary moment for scientists, like the members of the GIMAP team, who were alongside geologists, computer scientists, researchers in the humanities and social sciences, and so on.

Over the 3 days of the festival, 300 festival-goers were welcomed by the Saint-Etienne edition. 

Pint of Science Saint-Etienne was supported by the Jean Monnet University Faculty of Medicine. 

Find out more about Pint of Science...

Crohn's disease is a chronic inflammatory bowel disease affecting several million people worldwide, with an increasing incidence in developed and newly industrialized countries. The disease is characterized by alternating periods of relapses and remissions, the onset of complications and the development of resistance to treatment. All of these events remain unpredictable, which calls for a much better understanding of the cellular and molecular elements involved in this pathology, in the hope of improving diagnosis, management and treatment of patients.

Genomic studies have identified a number of risk alleles, particularly those linked to autophagy, a cellular function essential to all cells in the body. Autophagy plays a crucial role in maintaining the balance and functionality of the body's cells (cellular homeostasis). It is also central to the immune response, enabling the degradation of intracellular microorganisms, for example, or regulating the intensity of inflammatory responses.

Nevertheless, despite the identification of these at-risk alleles, no data has ever really demonstrated the impact of autophagic gene polymorphism on autophagic activity in Crohn's patients.

To answer this question, researchers at the Centre International de Recherche en Infectiologie (CIRI - Inserm/UCBL/CNRS/ENS de Lyon) have developed a new approach. By precisely measuring the dynamic properties of autophagic flow in cells from Crohn's disease patients, they have identified for the first time an autophagic flow defect in patients expressing a polymorphism affecting an autophagy gene.

“In these patients, the level of autophagy is reduced, as is the rate at which cytosolic elements are degraded”, explains Aurore Rozières (Maîtresse de Conférences at UCBL), who led this work.

This study, published in Autophagy, is the first to characterize autophagic flux from patient cells, and opens up important prospects for understanding Crohn's disease and the possible identification of new molecular targets for diagnosis and/or future treatments.

Credits: Mathieu Martin - Université Claude Bernard Lyon 1

La capacité des vaccins à ARNm intramusculaires contre le SARS-CoV-2 à induire une réponse anticorps au niveau des muqueuses reste encore débattue.

Cette étude réalisée à partir des essais COVICOMPARE-M et COVICOMPARE-P consiste à comparer la réponse humorale de personnes vaccinées contre le Covid-19 par des vaccins à ARNm. Concrètement, il s’agit d’analyser, au niveau salivaire, la réponse des anticorps à la vaccination des sujets naïfs (non infectés par le SARS-CoV-2 avant ou entre les phases de vaccination), à celle des sujets ayant été infectés avant la vaccination (pré-infectés).

Au total, 427 participants ont été inclus dans cette étude, parmi lesquels 120 pré-infectés. Entre février et juillet 2021, les participants naïfs ont reçu deux doses du vaccin Moderna ou Pfizer-BioNTech. Les participants pré-infectés, quant à eux, n’ont reçu qu’une dose du vaccin Pfizer. Les échantillons ont été recueillis avant la première dose (J1), puis avant la deuxième (J29), ensuite à J57 et à J180.

Les anticorps IgA¹ salivaires spécifiques du SARS-CoV-2 sont détectés de manière plus importante chez les sujets pré-infectés que chez les sujets naïfs. Toutefois, après vaccination, une augmentation de faible intensité du taux d’IgA est constatée chez les participants non pré-infectés ayant reçu le vaccin Moderna.  En comparaison, les anticorps IgG spécifiques du SARS-CoV-2 sont largement détectés dans la salive après vaccination aussi bien chez les sujets naïfs, que chez les pré-infectés. Dans les deux cas, les taux d’anticorps IgA et IgG mesurés au niveau salivaire sont fortement corrélés aux taux sériques, indiquant une vraisemblable diffusion du sang vers la salive.

Les résultats de cette étude montrent que la vaccination ARNm est associée à une très faible immunité spécifique des muqueuses, mais à des niveaux beaucoup plus faibles chez les participants naïfs. D’autres études sont nécessaires pour déterminer l’association entre les taux d’IgA salivaires spécifiques et la prévention de l’infection ou de la transmission du SARS-CoV-2.

Les essais COVICOMPARE-P et COVICOMPARE-M ont été labellisés Priorité Nationale de Recherche par le Comité ad-hoc de pilotage national des essais thérapeutiques et autres recherches sur l’épidémie de Covid-19 (CAPNET). Cette étude a été conduite par le réseau F-CRIN I-REIVAC, réseau d’excellence dédié à l’investigation clinique en vaccinologie, avec le soutien scientifique et financier de l’ANRS Maladies infectieuses émergentes, du ministère de la Santé et de la Prévention et du ministère de l’Enseignement supérieur, de la Recherche et de l’Innovation.

Retrouvez l'étude publiée dans le JAMA Network Open.

Au CIRI, Stéphane Paul (équipe GIMAP) et Jean-François Nicolas (équipe EIA) ont participé à cette étude.

¹. Les anticorps IgA sont principalement retrouvés dans les sécrétions (salive, larmes, sécrétions digestives et pulmonaires). On les trouve également dans le sang en quantités beaucoup plus faibles que celles des anticorps IgG. Il existe une forme particulière d’IgA, l’IgA sécrétoire, qui n’est retrouvée que dans les sécrétions ou elle joue un rôle antiviral particulièrement efficace.

Books are in French.

Une brève histoire de la microbiologie

De la découverte des bactéries et des virus à la révolution de la génomique

The book is divided in seven sections:

• « Des miasmes à la naissance de la bactériologie »
• « L'âge d'or de la bactériologie »
• « Naissance de la virologie »
• « Développements dans l'identification microbienne au cours du XXe siècle »
• « Évolution du séquençage de l'ADN et de l'ARN »
• « Principales applications de la biologie moléculaire en microbiologie »
• « Quelques découvertes marquantes de l'époque moderne »

These sections provide an insight into the tremendous developments in microbiology, from the first bacterial isolations from potatoes to the most recent sequencing methods, which have led to exceptional advances in the diagnosis and treatment of infectious diseases.

Book by Jean Freney et Frédéric Laurent published by editions ESKA - Médecine.

Frédéric Laurent is a hospital practitioner and a researcher, specialised in phages, in StaPath team.

More about this book...

L'ère des pandémies : COVID, les avancées de la recherche

Covid 19, l’histoire naturelle d’une maladie. Que dit la science sur les risques d’une nouvelle ère épidémique ?

Has the world entered a new epidemic era? What does science have to say? For several years now, scientists have been warning of the emergence of new diseases and the influence of environmental and social factors on health. Covid, and the health crisis it provoked, has precipitated a new awareness of the dangers posed to humanity by viruses, coronaviruses and other variants. In this book, researchers, physicians, biologists and epidemiologists set out to tell the "natural history of this disease": to recount its pandemic history and the questions it has raised, to understand viruses and coronaviruses, their differences, their location, their modes of transmission and the risks of crossing species, to take stock of the mechanisms of infection, replication and the notions of mutation and recombination. Beyond the polemics, the book takes stock of advances in research into this type of disease, as well as vaccination to protect against it. An essential review of a pandemic that has often been treated more in terms of its medical and health aspects than its scientific ones. This is a major contribution by scientists to the general public, enabling us today to better measure the risks of this new pandemic era, and to provide keys to protection against it.

A cherche midi book produced with the CNRS, the Institut écologie et environnement (INEE) and the Institut national des sciences biologiques (INSB).
Collective work edited by Florence Débarre, Agnès Mignot, Serge Morand, Françoise Praz
Foreword by Arnaud Fontanet

Amandine Le Corf, PhD student (CNRS), and Lucie Etienne, Head of research (CNRS) in the LP2L team, and Olivier Terrier, research fellow in the VirPath team, each wrote a chapter of this book.

Pour en savoir plus... 

David Durantel has been a member of the ISAR for a long time and is currently president of the Finances committee. Il was also awarded with the ISAR Prusoff in 2021.

Congratulations!

More about the ISAR...

Manuel Rosa-Calatrava (VirPath team) and Guy Boivin (CHU Québec - Université Laval research center), co-directors of RESPIVIR, were honored for their commitment, along with their teams from Quebec and Lyon, to research into infectious respiratory diseases and the application of their innovations through university-industry collaborations and the creation of university start-ups and spin-offs.

The partnership agreement between our supervisory bodies and Université Laval was formalized with the support of the Ministère des Relations Internationales et de la Francophonie du Québec and the MESRI, with the signature of Sophie d'Amour, Rector of Université Laval, Antoine Petit, CEO of CNRS and Frédéric Fleury, President of Université Claude Bernard Lyon 1, under the patronage of Sylvie Retailleau, Minister of Higher Education, Research and Innovation, and Pascale Déry, Minister of Higher Education of Quebec.

For more information on RESPIVIR: https://respivir.io/

La pandémie de COVID-19 a attiré l'attention sur l'impact sanitaire, économique et social considérable des virus respiratoires dans le monde. Chaque année, les infections respiratoires aiguës font partie des trois premières causes de décès et d'invalidité chez les enfants et les adultes. Bien que la préparation à des pandémies potentielles soit nécessaire, il est aussi important de considérer l’impact négatif de la circulation virale saisonnière sur la santé. Ainsi, des efforts pour améliorer les mesures de prévention contre cette circulation virale saisonnière sont nécessaires.

Dans le cadre d'une politique globale de santé publique et de prévention des infections aux virus respiratoires, la collecte d’informations est fondamentale. Ainsi, grâce à VIRESP, plusieurs types de données seront collectés, notamment : les caractéristiques des souches virales, leur évolution et la variation saisonnière. Une attention particulière sera portée aux populations les plus vulnérables à l'infection et sur la gravité de la maladie. Ces données fournissent un support scientifique aux prises de décisions sanitaires, au développement de vaccins, aux recommandations vaccinales ou à d'autres stratégies de prévention et de traitements.

Un projet multidisciplinaire

Le projet de recherche VIRESP permettra de développer des méthodologies, des techniques et des outils afin d’analyser le risque d'infection et le taux de morbidité des maladies dans différentes populations, ainsi que de déterminer les bénéfices des programmes de vaccination.

La création de cette nouvelle chaire industrielle s’inscrit pleinement dans la stratégie partenariale public/privé de l’UCBL, des HCL et de Sanofi pour renforcer les collaborations afin de répondre aux grands défis de santé publique dans le domaine de l’infectiologie. L’Agence nationale de la recherche, qui a notamment pour missions de développer, renforcer, et diversifier les relations entre le monde académique et les entreprises, cofinancera la chaire industrielle VIRESP à hauteur d’un million d’euros sur quatre ans.

La valorisation des résultats issus de cette chaire constitue aussi un enjeu majeur pour les partenaires.

La chaire VIRESP assurera par ailleurs la supervision d’un programme de formation de haut niveau et international (Master, doctorat et post-doctorat) pour travailler sur des projets collaboratifs à dimension internationale. L’Université Claude Bernard Lyon 1 sera notamment engagée dans un programme d’échanges d’étudiants avec l’Afrique du sud.

Ce projet s'appuiera sur une équipe multidisciplinaire hautement qualifiée de chercheurs, cliniciens, épidémiologistes, méthodologistes, statisticiens et analystes. Les entrepôts de données de santé et l'expertise auprès de plusieurs partenaires aux niveaux local, national et mondial seront mobilisés afin de fournir :

1. Des outils analytiques pour mieux comprendre l’impact des virus respiratoires et l’efficacité des vaccins contre ceux-ci, ainsi que des indications pour améliorer le développement de nouveaux vaccins ;

2. Des approches sur les améliorations à apporter aux systèmes actuels de surveillance passive et active des virus dans le but de renforcer la préparation aux pandémies et d'accroître la résilience de l'industrie pharmaceutique ;

3. Des moyens d'identifier de meilleures cibles virales pour la recherche et le développement afin de mettre au point des vaccins mieux adaptés aux besoins des populations à risque ;

4. Un algorithme permettant d'identifier les menaces d’apparition de nouveaux virus et de surveiller les virus récurrents connus ;

5. Un programme de diffusion et de renforcement des capacités axé sur l'épidémiologie, la modélisation, l'analyse avancée de données et la bio-informatique.

6. Une supervision des étudiants en Master et en thèse recrutés dans le cadre de la chaire industrielle et contribuer aux programmes de formation localement et à travers le réseau des partenaires du CERP pour accélérer le transfert de connaissances obtenues grâce à ce partenariat public-privé. Cette formation a également vocation à attirer de nouveaux talents parmi lesquels des étudiants étrangers issus d’établissements prestigieux

Un écosystème unique sur les maladies infectieuses

Le Centre d'Excellence sur les Pathogènes Respiratoires (CERP) du Centre International de Recherche en Infectiologie (CIRI), une unité de recherche exceptionnelle affiliée à l'Université Claude Bernard Lyon 1 (UCBL), ainsi que Sanofi et les Hospices Civils de Lyon (HCL), forment un écosystème unique sur les maladies infectieuses. Ce programme ambitieux vise à positionner la France au cœur de la recherche sur les virus respiratoires et des décisions relatives à la préparation aux pandémies, ce qui lui permettra de renforcer son influence européenne et internationale sur les partenariats public-privé nécessaires pour y faire face. Grâce à ce programme de recherche multidisciplinaire et à ses fortes connexions internationales, des résultats pertinents et collaboratifs seront produits afin de maintenir l'innovation dans la recherche et de conseiller l'investissement industriel.

Lors de ce lancement officiel, les partenaires se sont réjouis de cette collaboration.

En ouverture de ce temps fort, Frédéric FLEURY a tenu à rappeler que « Viresp est la deuxième chaire industrielle obtenue par l’UCBL et les HCL sur les sept chaires lauréates en France en 2023. Ces succès témoignent à la fois de l’excellence de la recherche en santé produite par le CHU et l’Université ainsi que leur capacité à attirer des grands chercheurs internationaux comme Marta Nunes et des grands acteurs industriels comme Sanofi. Avec cette chaire industrielle qui s’inscrit dans la continuité de la dynamique insufflée par la création du CERP (Centre d’excellence sur les pathogènes respiratoires), nos institutions intensifieront encore davantage leur recherche sur les maladies infectieuses et leur expertise en vaccinologie, consolidant la position du site lyonnais considéré comme une référence internationale dans le domaine. »

Ilias ILIOPOULOS, Président du comité d’évaluation scientifique des « Chaires industrielles » de l’ANR, a déclaré que : « La chaire industrielle VIRESP, soutenue par l’ANR, illustre parfaitement l’ambition de ce dispositif spécifique de soutien à la recherche partenariale public-privé. En effet, le programme chaire industrielle poursuit un triple objectif : construire et structurer des projets de recherche collaborative dans des domaines prioritaires et stratégiques pour les acteurs publics et privés via un partenariat fort et durable ; permettre à des enseignants-chercheurs ou des chercheurs de notoriété internationale, de travailler sur un programme de recherche ambitieux, innovant et de portée industrielle ; enfin, d’accueillir et de former des jeunes scientifiques en master et doctorat ainsi que des post-doctorants. L’écosystème Lyonnais au sein duquel évoluera la chaire VIRESP offre un environnement idéal pour le succès de ce projet. Depuis 2012, l’ANR a déjà cofinancé plus d’une soixantaine de Chaires Industrielles. »

Raymond LE MOIGN, Directeur Général des Hospices Civils de Lyon a confirmé également que « L’attribution de cette chaire industrielle est une grande réussite pour le Centre d’Excellence des Pathogènes Respiratoires (CERP), créé il a seulement un an et demi collaboration avec Sanofi et l’Université Claude Bernard Lyon 1. Ce financement, et la confiance témoignée par l’ANR dans cette chaire industrielle VIRESP, permettra de mener un programme de recherche très ambitieux dans le domaine de l’infectiologie qui est au cœur de la stratégie des Hospices Civils de Lyon. C’est une nouvelle illustration de la force des HCL et de l’écosystème lyonnais à déployer des partenariats public -privé originaux au service de la recherche en santé. »

« Nous sommes ravis de collaborer à la création de la chaire VIRESP. Ce projet de recherche s’inscrit pleinement dans la volonté de Sanofi de renforcer notre contribution en matière de santé publique et notre contribution dans la prévention des maladies respiratoires. », déclare pour conclure Bogdana COUDSY, Directrice médicale Sanofi Vaccins.

Nous vous invitons à découvrir le communiqué de presse complet.

Retrouvez cette actualité sur le site de l'Université Lyon 1.

Texte : Université Claude Bernard Lyon 1

Rare Disease Day

La Journée des maladies rares est le mouvement mondial coordonné sur les maladies rares, qui œuvre pour l'équité en matière d'opportunités sociales, de soins de santé et d'accès au diagnostic et aux thérapies pour les personnes atteintes d'une maladie rare.
Rare Disease Day is the globally-coordinated movement on rare diseases, working towards equity in social opportunity, healthcare, and access to diagnosis and therapies for people living with a rare disease. Since its creation in 2008, Rare Disease Day has played a critical part in building an international rare disease community that is multi-disease, global, and diverse– but united in purpose. Rare Disease Day is observed every year on 28 February (or 29 in leap years)—the rarest day of the year. Rare Disease Day was set up and is coordinated by EURORDIS and 65+ national alliance patient organisation partners. Rare Disease Day provides an energy and focal point that enables rare diseases advocacy work to progress on the local, national and international levels.

Find out more...

Research conducted on rare diseases at the CIRI

At the CIRI, 2 teams conduct research on auto-immune and auto-inflammatory rare diseases : 

• LYACTS team (T. Walzer), linked to the reference center RAISE via Alexandre Belot.
• IB2A team (T. Henry), linked to the reference center CéRéMAIA via Yvan Jamilloux.
   

Those teams are a part of the FAI²R network, a health network about rare auto-immune and auto-inflammatory diseases. The network is funded and led by the Health Minister. FAI²R federates resources and expertise to facilitate the care, diagnosis and management of adult and pediatric patients.

Those teams study especially pediatric onset lupus, familial Mediterranean fever and ROSAH syndrome.

A huge thank you to the clinicians working on rare diseases, and to the patients ! 

Awards 

On December 13, the ceremony celebrated the exceptional contribution of members of the university community to the reputation of Université Claude Bernard. The RESPIVIR France-Canada International Associated Laboratory, created by Manuel Rosa-Calatrava, co-director of the CIRI's VirPath team, with Guy Boivin's team at Université Laval, has been selected for the AAP ETOILES 2023, which supports excellence in research and innovation in line with the institution's strategic priorities. UCBL1's support for the international dynamics of VirPath's research, in the form of a PhD grant, complements and synergizes funding from Université Laval, CNRS (IRP2023) and the Auvergne-Rhône-Alpes Region (Pack Ambition International).

Manuel Rosa-Calatrava's team also received the Innovation award for its outstanding contribution to the valorization of innovation through its involvement in numerous public-private R&D partnerships, the building up of a portfolio of patents and the spin-off of innovative biotechnology companies and technological services. Based on integrated fundamental and translational research, the team's innovation and development policy is supported by its technological research platform, Virnext, and by its subsidiaries Ezus Lyon University and Lyon Ingénierie Projet. It aims to create scientific, medical, economic and societal value, and is part of the national and European sovereignty approach to protection against emerging and re-emerging infectious diseases.

the research program of the respivir france - canada international associate laboratory 

CNRS Biology has selected the RESPIVIR International Associated Laboratory France - Canada (Université Claude Bernard Lyon 1 - Université Laval) research program as part of the International Research Program 2023 (IRP) call for projects.

A partnership between Université Laval and Université Claude Bernard, RESPIVIR was created by Manuel Rosa-Calatrava (VirPath, Centre International de Recherche en Infectiologie) and Guy Boivin (LVMC, Centre de recherche du CHU Québec - Université Laval) to conduct integrated fundamental, translational medical and applied research on emerging and re-emerging respiratory viruses. As part of the dynamic Franco-Canadian joint committee (CMFC) on science, technology and innovation, RESPIVIR is helping to structure and strengthen the strategic international link between France and Canada, and particularly between the province of Quebec and our Auvergne-Rhône-Alpes region.

It's a wonderful recognition of the know-how and international research dynamism of Manuel Rosa-Calatrava's team at CIRI, and we're very honoured and proud of it. The CNRS funding complements those of Université Laval, UCBL1 (ETOILE 2023) and the Auvergne-Rhône-Alpes Region (AAP Ambition International).

more about this

Évènement de valorisation du Laboratoire International Associé France-Canada RespiVIR

L'innovation à Lyon 1 mise à l'honneur

© :Eric Le Roux / Direction de la communication Université Lyon 1

In April 2020, a particular form of shock associated with myocarditis and systemic inflammation was identified in children, manifesting following SARS-CoV2 infection. This phenomenon was named Pediatric Inflammatory Multi-Systemic Syndrome (PIMS or MIS-C) and was considered a new clinical entity. It is the most severe form of SARS-CoV-2-associated disease in children.

This syndrome appeared around 4 weeks after a COVID-19 infection, most often asymptomatic, in around one case per 10,000 infections in children at the time of the first waves. Having affected almost 1,100 children in France, the incidence has now fallen, and PIMS are now very rare.

In 2021, the team led by Prof. Alexandre Belot¹ , a pediatrician at the Hospices civils de Lyon's Hôpital Femme Mère Enfant (HFME) and researcher at the Centre International de Recherche en Infectiologie (CIRI - Inserm/CNRS/ENS de Lyon/Université Claude Bernard Lyon 1) had discovered a marker for the disease corresponding to a specific activation of a family of white blood cells.

In a new study published in the New England Journal of Medicine, the same team, with the help of international collaborators, was able to trace cases of this disease occurring before 2019, not linked to SARS-CoV2. This unidentified disease at the time was often confused with infectious toxic shock, or Kawasaki disease, in its form with shock.

"We initially studied over a hundred children hospitalized in Lyon's intensive care unit between 2006 and 2018 for shock with hypotension and inflammation. We were surprised to find the PIMS marker in 3 children. By going back over the symptoms of these children, we discovered that they corresponded exactly to the presentation of MIS-C described in 2020 with COVID-19," reports Pr Belot. With more than 13 years of hindsight for some cases, these children did not present any recurrence or otable symptoms during the COVID pandemic.

A total of six cases of PIMS/MIS-C have been reported since 2010, two of which suggest prior infection with other coronaviruses (including seasonal), raising the hypothesis of a more general role for coronaviruses in post-infectious inflammatory manifestations.

This syndrome may therefore occur in the absence of SARS-CoV-2, broadening our understanding of pediatric inflammatory diseases. This work will enable us to consider earlier management of children, and will also encourage us to pay particular attention to this syndrome in the event of new epidemics of respiratory infections, notably with Coronavirus.

1. CIRI's Lymphocyte Activation and Signal Transduction Team (LYACTS)

Source
Pre-COVID-19 and SARS-CoV-2-negative cases of Multisystem Inflammatory Syndrome in Children
Benezech S°, Khoryati L°, Cognard J, Netea S, Khan T, Moreews M, Saker K, De Guillebon JM, Khaldi-
Plassart S, Pescarmona R, Viel S, Malcus C, Perret M, Ar Gouilh M, Vabret A, Venet F, Remy S, Chopin E,
Lina G, Vandenesch F, Rousseaux N, Bastard P, Zhang SY, Casanova JL, Trouillet-Assant S, Walzer T,
Kuijpers T, Javouhey E, Dauwalder O, Marr N, Belot A. N Engl J Med (2023).
Doi : 10.1056/NEJMc2307574

Scientific contact
Alexandre Belot, Pediatrics professor at the Université Claude Bernard Lyon 1 and hospital practitioner at the Hospices Civils de Lyon (PUPH), CIRI & HFME member
alexandre.belot@chu-lyon.fr | tel : +33 (0)4 27 85 61 26

About the PEPR MIE

The PEPR MIE call for projects (priority research programs and equipment for emerging infectious diseases) is managed by Inserm through the ANRS Emerging Infectious Diseases Program. It is part of the Innovation santé 2030 (France 2030) plan, which aims to strengthen French and European preparedness and response capacity in the event of a new health crisis. As part of a "One Health" approach, it funds interdisciplinary projects, with a total budget of 22 million euros.

The objectives are threefold. The aim is to gain a better understanding of the emergence or re-emergence of infectious diseases, in order to develop diagnostic, protection and treatment tools. In addition, one axis focuses on the implementation of health policies based on scientific evidence and adapted to the specific context of the crisis.

The PEPR MIE is divided into three components:

• Component 1: Accelerating the acquisition of fundamental knowledge on emerging infectious diseases
• Component 2: Promote innovation and develop new treatments, vaccines and other prevention, diagnostic and surveillance tools for emerging infectious diseases.
• Component 3: Enable public policies and society to cope with epidemic crises

2023 laureates projects that involve the ciri

Three projects led by a CIRI researcher

Thomas HENRY (Inserm, I2BA team) is coordinating the Ft6SS-Meca project (component 1). 

The Ft6SS-Meca project will study the structure, molecular mechanisms of secretion and function of effectors of the secretion system (T6SS) of the bacterium Francisella tularensis (threat agent). The expected results could lead to the long-term identification of new treatments specifically targeting this secretion system, a key virulence factor.

Sylvain BAIZE (Institut Pasteur, UBIVE team) coordinates the COPAFLICT project (component 1). 

The aim of the COPAFLICT project is to improve fundamental knowledge of viral hemorrhagic fevers and offer new perspectives for their diagnosis and treatment. To achieve this, it will study the immunopathogenesis associated with Lassa fever virus (lightning hemorrhagic fever), to identify immune pathways of interest for the development of new therapeutic strategies targeting the host response.

Alexandre GAYMARD (HCL, VirPath team) coordinates the VORTEX project (component 2). 
Sophie JARRAUD (HCL, LegioPath team) and Sophie TROUILLET-ASSANT (HCL, VirPath team) are also part of the VORTEX consortium.

The aim of the VORTEX project is to develop a non-invasive diagnostic method based on the results of patients' exhaled air analysis. It aims to identify signatures of volatile organic compounds specific to a pathogen or to the immune response of patients, in order to improve the management and monitoring of emerging respiratory infections.

Three projects involving CIRI researchers in their consortium

Oliver TERRIER (ENS de Lyon, Université Claude Bernard Lyon 1, VirPath team) is part of the consortium behind the 3D-LUNGO project (component 1).

Coordinated by Lisa CHAKRABARTI (Institut Pasteur), this project aims to provide 3D tissue models, based on the study of the susceptibility of nasal or bronchial mucosa and pulmonary alveoli to respiratory viruses, to rapidly and collaboratively test the lesions that could be induced by newly emerging respiratory pathogens.

Bruno LINA (Institut des Agents Infectieux, HCL - Hopital de la Croix-Rousse, VirPath team) is part of the consortium behind the SISP&EAU project (component 1).

Coordinated by Pierre-Yves BOELLE (Institut Pierre Louis d'Epidemiologie et de Santé Publique, Sorbonne Université), this project aims to build and validate a surveillance model for respiratory viruses in France, integrating clinical cases and wastewater. It will set up the detection and monitoring of viral strains causing respiratory infections to characterize the dynamics of virus circulation in the general population. It will perpetuate the technological, mathematical and IT tools developed for epidemiological surveillance during the COVID-19 pandemic.

Cyrille Mathieu (CIRI Centre International de Recherche en Infectiologie, Inserm, CNRS, ENS Lyon, Univ. Claude Bernard Lyon 1, NITROVIRE group), Pierre-Olivier VIDALAIN (Inserm, CNRS, ENS, Université Claude Bernard Lyon 1, VIRIMI team) and Vincent LOTTEAU (Inserm, VIRIMI team) are part of the consortium behind the NIPAH-LISA project (part 2).

Coordinated by Sonia LONGHI (Aix Marseille Université, CNRS), this project focuses on airborne infections by viruses of the highly pathogenic Paramyxovirinae family (including Nipah virus), and aims to develop a multi-component antiviral treatment for these infections.

Congratulations to all the winners! 

See more information and the list of all winning projects on the ANRS website.

Source : ANRS.fr

Translated with DeepL

The PHE3ID/CERP research team has been awarded with one of the first Projets d’Amorçage supported by SHAPE-Med@Lyon.

The proposed project “EASIER-COHORT: ExtrAction of Symptoms from electronIc hEalth Records to create automatic COHORTs” is among the 10 selected projects and will be developed during 2 years in collaboration with the team of Prof Angela Bonifati at LIRIS.

EASIER-COHORT aims at developing natural language processing (NLP) techniques to retrieve automatically unstructured information from patients’ records, such as symptoms and comorbidities, to address epidemiological questions.

The first projects will be focussed on viral respiratory infections especially for detection, diagnosis and outcome in hospitalized patients. Results will be helpful for education, prevention, including vaccine, and improvement of care in patients at risk of such infections.

https://www.shape-med-lyon.fr/actualites/le-projet-shape-medlyon-devoile-les-10-laureats-de-son-appel-a-projets-damorcage/

The COVID-19 pandemic showed the devastating impact of an unknown infectious disease. The lack of prevention tools and of treatments worsened the crisis. Three years later, the cost to our society is high, with repercussions all over the world.

Now more than ever, the consequences of the mergence of new viruses, particularly respiratory viruses, is a major public health concern. The emergence of viral diseases is set to accelerate, partly due to climate change. 

It is with the idea of better facing these potential emerging viruses that the "chaire industrielle" REVIDA (infections REspiratoires VIrales - du DiAgnostic au Pronostic / viral respiratory infections - from diagnosis to prognosis) was formed, led by Dr Sophie Trouillet-Assant (UCBL/HCL).

Hosted by the Université Claude Bernard Lyon 1 and working in the mixed laboratory HCL/UCBL/bioMérieux, she will combine the work from the Centre international de recherche en infectiologie (CIRI – CNRS/Inserm/Université Claude Bernard Lyon 1/ENS de Lyon), the Hospices Civils de Lyon and from bioMérieux to offer new - efficient and innovating - diagnosis solutions, which will improve management of patients suffering from respiratory infections.

The goal is to identify more quickly the people suffering from viral infections, no matter the virus, in order to react faster if a new pandemic were to happen and to be able to quickly predict who would be particularly likely to develop a severe form of the disease, and thus improve management of patients.

Dans cette optique, le projet ambitieux et innovant de la chaire REVIDA étudiera la réponse immunitaire des patients infectés pour mettre au point de nouveaux outils diagnostiques et pronostiques rapides des infections virales respiratoires sans recherche systématique de l’agent pathogène.

With this in mind, the ambitious and innovative project of the REVIDA chaire will study the immune response of infected patients to design new diagnosis and prognosis tools able to quickly detect viral respiratory infections without having to look for the specific pathogen.

You can find out more in the whole press release here.

You can also find this news on the websites of the Université Claude Bernard Lyon 1 and the Université Claude Bernard Lyon 1

Text (french version) : Béatrice DIAS, Directrice de la communication de l'Université Claude Bernard Lyon 1

Lead image : Launch of the chaire Revida, from left to right : Jérôme Honnorat, Vice-président recherche délégué secteur "Santé" de l’UCBL, Ilias Iliopoulos, président référent du comité « chaires industrielles » de l’ANR, Frédéric Fleury, président de l’Université Claude Bernard Lyon 1, Aurore Fleurie, Senior Manager R&D bioMérieux, Coresponsable de l’unité mixte HCL-UCBL-bioMérieux, Sophie Trouillet-Assant, chercheuse au CIRI, responsable de l’unité mixte HCL-UCBL-bioMérieux, Alexandre Pachot, Directeur de la Recherche en Santé chez HCL, François Lacoste, Directeur Exécutif Recherche & Développement chez bioMérieux, Bruno Lina, chef de service laboratoire de virologie, directeur du CNR des virus respiratoires, François-Loic Cosset, directeur du CIRI 

Every year, Sidaction organizes a laboratory visit for its donors. A research team is invited to open its doors and give an insight into the world of research, particularly in the field of HIV. This year, CIRI and the LP2L team welcomed donors from the Lyon area to their laboratory on Thursday October 12.

Presentation of a research project by Alexandre Legrand. Photo credit: Sidaction

The evening began with short presentations by Jennifer Pasquier about Sidaction, then by Andrea Cimarelli about the ENS de Lyon and CIRI. Lucie Etienne then presented the HIV research conducted by the LP2L team. To round off this introductory phase, Alexandre Legrand and Charlotte Vadon, PhD students, presented their current research projects.

Laboratory visit and demonstration of manipulation under safety weighing cabinets, by Amandine Le Corf, Rémi Demeure and Séverine Deymier. Photo credit: Sidaction

Donors were then given a hands-on tour of the laboratories. Members of the LP2L team were involved in showing them around the premises, and even letting them handle the equipment. The program included tours of labs P2 and P3, the bioinformatics section, banana DNA extraction, and discovery of cutting-edge tools such as FACS and the confocal fluorescence microscope. This initiative was made possible thanks to the collaboration of the SFR BioSciences flow cytometry platform and PLATIM. 

LP2L team members report the enthusiasm of visitors during these laboratory visits. The conversation continued over cocktails and research posters. Donors were able to ask students, engineers and researchers all their questions. 

The evening was clearly a success! The feedback from visitors was very positive. Very involved, they had many questions, particularly about treatments. They also pointed out that they "hadn't imagined labs like this", a sign of the importance of these public-research encounters. It was also a very positive experience for the team. According to Lucie Etienne, this kind of encounter gives meaning to the research profession, and provides an opportunity for sharing with the public, as well as within the team. The enthusiasm, professionalism and involvement of the young team members was underlined by the donors, the Sidaction team and the rest of the team.

LP2L team. Photo credit: Sidaction.

This team already had a strong link with Sidaction. Andrea Cimarelli and Lucie Etienne have benefited from financial support from Sidaction at key moments in their careers. Currently, Sidaction is funding a 24-month project involving 5 members of their team, as well as the 4-year position of Alexandre Legrand (PhD student). In return, the team contributes to Sidaction's work. Andrea Cimarelli was a member of the organization's Medical and Scientific Committee, and Lucie Etienne is currently a member. She has also written an article for Sidaction's magazine, Transversal, on the place of women in science and research. This laboratory visit strengthens this long-standing association, and paves the way for other potential future collaborations.

À Paris se déroule aujourd'hui et demain la 23e rencontre du Réseau National Hépatites virales organisée par l'AC42 de l'ANRS | Maladies infectieuses émergantes. François-Loïc COSSET, Directeur d'Unité du CIRI et Président de l'AC42 a ouvert cet événement.

Pendant 2 jours vont se succéder des sessions de présentations et de discussions, des invités et des remises de prix. Parmis les intervenants, il faut compter sur les membres du CIRI des équipes EVIR et HepVir !

Cette rencontre doit permettre de créer du dialogue entre les chercheurs et les médecins cliniciens autour des dernières avancées françaises en matière de recherche fondamentale et translationnelle sur les hépatites virales. C'est l'occasion de créer du lien entre la recherche clinique et la recherche fondamentale.

Retrouvez le programme complet en ligne ici.

Une retransmission en direct est accessible ici.

Download the press release

See the article online: CNRS / Inserm

Summary

A large proportion of the population has developed immunity to SARS-CoV-2 following infection and/or vaccination. In addition, some infected patients benefit from a so-called "hybrid" immunity when they have been vaccinated after their infectious episode. Scientists from Inserm, CNRS, Claude-Bernard Lyon 1 University and ENS Lyon within the Centre International de Recherche en Infectiologie (CIRI) are seeking to characterize the imprint left by exposure to SARS-CoV-2 through vaccination or the combination of both events on immune memory. The objective? To better understand the mechanisms of the immune response to the virus in order to improve patient management and optimize vaccine strategies. In a new study, scientists compared the immune memory of convalescent individuals, both vaccinated and unvaccinated against SARS-CoV-2, with that induced by vaccination in vaccinated individuals who had never beeń infected with the virus. Their results show that individuals vaccinated after infection are best protected from reinfection with SARS-CoV-2. The full article is published in the journal Science Translational Medicine.

The article

Prior SARS-CoV-2 infection enhances and reshapes spike protein-specific memory induced by vaccination
Veronique Barateau, Loic Peyrot, Carla Saade, Bruno Pozzetto, Karen Brengel-Pesce, Mad-Helenie Elsensohn, Omran Allatif, Nicolas Guibert, Christelle Compagnon, Natacha Mariano, Julie Chaix, Sophia Djebali, Jean-Baptiste Fassier, Bruno Lina, Katia Lefsihane, Maxime Espi, Olivier Thaunat, Jacqueline Marvel, Manuel Rosa-Calatrava, Andres Pizzorno, Delphine Maucort-Boulch, Laetitia Henaff, Mitra Saadatian-Elahi, Philippe Vanhems, Stéphane Paul, Thierry Walzer, Sophie Trouillet-Assant, and Thierry Defrance
Science Translational Medicine, 15 mars 2023
DOI: 10.1126/scitranslmed.ade0550

CIRI teams involved

• NOPAB 
• VirPath
• GIMAP
• ICL
• PHE3ID
• LYACTS
• Service BIBS

“Understand the pathogenic role of HERV-W envelope protein and develop novel prognostic markers and therapeutic targets for personalized treatment of COVID-19-associated syndromes”
These are the goals of a project involving researchers from 5 different EU countries.
This study has already produced evidence for the induction of a specific protein during COVID-19 disease. New information to guide predictive and personalized medicine may be obtained in the near future thanks to this discovery.

THE PROJECT

HERVCOV is the name of the project funded by the European Commission with a grant of almost 7 million euros that involves research centers, companies and associations from Croatia, France, Greece, Italy and Spain.

The study behind HERVCOV is focused on the HERV-W-ENV protein, a molecule found to be induced during SARS-CoV-2 infection and present at high levels in the blood of patients with severe COVID-19 and has been associated to the so-called “long COVID” disorders. Human Endogenous RetroVirus (HERV) represent about 8% of the human genome and their DNA copies were inserted after retroviral infections of germ cells that mainly occurred millions of years ago. The majority of their sequences are epigenetically silenced and/or have mutations disrupting their coding potential.

However, some HERV copies can be activated by different stimuli such as viral infections, and further produce pathogenic retroviral proteins like HERV-W ENV. This pathogenic protein is known to contribute to the onset and progression of several inflammatory and neurological diseases. During the COVID-19 pandemic, we have witnessed the activation of this protein expression in blood lymphocytes and in lungs of patients who are or have been infected with SARS-CoV-2.

THE PROJECT GOALS

Since 2019, more than 500 million SARS-CoV-2 infections have been recorded causing more than 6 million deaths in the world (source “Our World Data”, May 2022). Although most severe symptoms seem to be mitigated at this stage of the pandemic, numerous studies have demonstrated long term effects in recovered patients, affecting their neurological, gastrointestinal, cardiocirculatory systems and even mental health.

HERVCOV project aims to study the effect of SARS-CoV-2 infection on the HERV activation and resulting pathology in COVID-19 patients. This study could also offer important insights to other related diseases studying host responses in different contexts. Thanks to these studies, in the near future we shall be able to deliver specific health care approaches based on the analysis of biomarkers, disease symptoms and progression, and tailored to a personalized and precision medicine.
The identification of critical-factors and immune responses customized for each person will lead to the specific therapeutic interventions and adapted vaccination strategies.

THE PARTNERS

HERVCOV project is funded under the HORIZON-HLTH-2021-DISEASE call (Personalised medicine and infectious disease: understanding the individual host response to viruses) of the European Commission under the Horizon Europe Framework Programme and it will involve the following partners: Institut National de la Santé et de la Recherche Médicale (France), Ethniko Kai Kapodistriako Panepistimio Athinon (Greece), Rome Tor Vergata University (Italy), Instituto Aragonés de Ciencias de la Salud (Spain), Fundación Agencia Aragonesa para la Investigación y el Desarrollo (Spain), Geneuro Innovation SAS (France), Inserm Transfert (France), Klinicki Bolnicki Centar Rijeka (Croatia) and Frascati Scienza (Italy).

This project has received funding from the European Union’s Horizon Europe research and innovation program under grant agreement No 101057302.

The bacterium Acinetobacter baumannii is responsible for opportunistic infections (infections caused by germs that are usually not very pathogenic but that cause infections in people with a deficient immune system) and sometimes nosocomial infections (acquired in hospitals). A. baumannii infections are not very common but very difficult to treat. There are even cases of resistance to the last resort broad-spectrum antibiotics called carbapenems.
Resistance to several antibiotics (multi-resistance), when it includes resistance to carbapenems, has led the WHO to rank A. baumannii strains as priority in the search for new antibiotics.

Over the last decade, several genomic analyses of multi-resistant A. baumannii strains had indicated that the resistance genes, sometimes numerous, could be acquired from other bacteria of the same species or even from different species. The biological phenomenon at the origin of these gene transfer events remained to be determined. The study, co-authored by Maria-Halima Laaberki, lecturer at VetAgro Sup, and Xavier Charpentier, research director at Inserm and team leader at the International Centre for Infectious Diseases Research in Lyon (CIRI, CNRS/École Normale Supérieure de Lyon/INSERM/Université Claude Bernard Lyon 1), reveals the conditions in which these transfer events occur. Indeed, they demonstrate that a bacterium sensitive to an antibiotic is capable of acquiring the resistance of a neighboring bacterium in less than 4 hours, including resistance to carbapenems.

This active transfer, called natural transformation (discovered in 1928 by Frederick Griffith in pneumococcus and, since then, in many bacteria), occurs in the recipient bacteria, which is able to capture and incorporate into its genome the DNA of neighboring bacteria.

This transfer is extremely efficient and is obtained from small quantities of DNA naturally released by the resistant neighboring bacteria.

To obtain these results, the research team used both conventional and genome sequencing-based bacterial genetic techniques. The latter approach, used here as a transfer event mapping method, revealed that this bacterium is capable of acquiring more than 80 genes in a single transfer event. In a few hours, A. baumannii can thus modify more than 3% of its genome, giving it the ability to resist to many classes of antibiotics.

These results provide a better understanding of how this pathogen accumulates antibiotic resistance. In direct link with public health issues, the team is currently pursuing its research and working to determine in which environment this resistance is acquired and how to anticipate the appearance of new resistances.

This publication presents part of Anne-Sophie Godeux's university thesis on the emergence of resistance in A. baumannii, co-funded by VetAgro Sup and the LabEx ECOFECT supervised by Maria-Halima Laaberki.

Authors : Anne-Sophie Godeux, Elin Sveldhom, Samuel Barreto, Anaïs Potron, Samuel Venner, Xavier Charpentier, Maria-Halima Laaberki

Open access publication: https://doi.org/10.1128/mbio.02631-21

Ce prix est destiné à soutenir des travaux de recherche biomédicale sur les maladies ostéoarticulaires. Il récompense cette année le Pr Alexandre Belot, qui dirige l'unité de rhumatologie pédiatrique de lhôpital Femme Mère Enfant de Bron. Alexandre Belot est PU-PH UCBLI/HCL, il effectue ses travaux de recherche au CIRI dans l'équipe LYACTS dirigée par Thierry Walzer, où il étudie en particulier les mécanismes moléculaires impliqués dans des maladies auto-immunes rares, comme le lupus. 

En savoir plus sur tous les prix remis par la Fondation pour la Recherche Médicale en 2021.